The Sound of Interconnectivity; The European Vasculitis Society 2022 Report

Allyson C. Egan; Andreas Kronbichler; Irmgard Neumann; Alessandra Bettiol; Nicholas Carlson; Maria C. Cid; Giacomo Emmi; Seerapani Gopaluni; Lorraine Harper; Thomas Hauser; Mark A. Little; Raashid A. Luqmani; Alfred Mahr; Mark McClure; Aladdin J. Mohammad; Karl Emil Nelveg-Kristensen; Sophie Ohlsson; Chen Au Peh; Matthew Rutherford; Beatriz Sanchez Alamo; Jennifer Scott; Mårten Segelmark; Rona M. Smith; Wladimir M. Szpirt; Gunnar Tómasson; Giorgio Trivioli; Augusto Vaglio; Michael Walsh; Maria Wester Trejo; Kerstin Westman; Ingeborg M. Bajema; David R.W. Jayne

doi:10.1016/j.ekir.2022.05.018

The Sound of Interconnectivity; The European Vasculitis Society 2022 Report

Allyson C. Egan^*, Andreas Kronbichler, Irmgard Neumann, Alessandra Bettiol, Nicholas Carlson, Maria C. Cid, Giacomo Emmi, Seerapani Gopaluni, Lorraine Harper, Thomas Hauser, Mark A. Little, Raashid A. Luqmani, Alfred Mahr, Mark McClure, Aladdin J. Mohammad, Karl Emil Nelveg-Kristensen, Sophie Ohlsson, Chen Au Peh, Matthew Rutherford, Beatriz Sanchez AlamoJennifer Scott, Mårten Segelmark, Rona M. Smith, Wladimir M. Szpirt, Gunnar Tómasson, Giorgio Trivioli, Augusto Vaglio, Michael Walsh, Maria Wester Trejo, Kerstin Westman, Ingeborg M. Bajema, David R.W. Jayne

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

The first European Vasculitis Society (EUVAS) meeting report was published in 2017. Herein, we report on developments in the past 5 years which were greatly influenced by the pandemic. The adaptability to engage virtually, at this critical time in society, embodies the importance of networks and underscores the role of global collaborations. We outline state-of-the-art webinar topics, updates on developments in the last 5 years, and proposals for agendas going forward. A host of newly reported clinical trials is shaping practice on steroid minimization, maintenance strategies, and the role of newer therapies. To guide longer-term strategies, a longitudinal 10-year study investigating relapse, comorbidity, malignancy, and survival rates is at an advanced stage. Disease assessment studies are refining classification criteria to differentiate forms of vasculitis more fully. A large international validation study on the histologic classification of anti-neutrophil cytoplasmic antibody (ANCA) glomerulonephritis, recruiting new multicenter sites and comparing results with the Kidney Risk Score, has been conducted. Eosinophilic granulomatosis with polyangiitis (EGPA) genomics offers potential pathogenic subset and therapeutic insights. Among biomarkers, ANCA testing is favoring immunoassay as the preferred method for diagnostic evaluation. Consolidated development of European registries is progressing with an integrated framework to analyze large clinical data sets on an unprecedented scale.

Original language	English
Pages (from-to)	1745-1757
Number of pages	13
Journal	Kidney International Reports
Volume	7
Issue number	8
DOIs	https://doi.org/10.1016/j.ekir.2022.05.018
Publication status	Published - Aug 2022

Bibliographical note

Funding Information:
The authors acknowledge Dr. Elena Gelain (Nephrology Unit, Meyer Children's Hospital and Department of Biomedical Experimental and Clinical Sciences “Mario Serio,” University of Firenze, Firenze, Italy) for coordinating several EGPA and IgAV activities. EUVAS receives funding from Vifor Fresenius Medical Care Renal Pharma Ltd. Hoffman La Roche, InflaRx, and the charity Vasculitis UK. NC is supported by The Danish Heart Foundation. KENK was funded privately by Helen and Ejnar Bjørnows Foundation and Knud Højgaards Foundation.

Funding Information:
The authors acknowledge Dr. Elena Gelain (Nephrology Unit, Meyer Children’s Hospital and Department of Biomedical Experimental and Clinical Sciences “Mario Serio,” University of Firenze, Firenze, Italy) for coordinating several EGPA and IgAV activities. EUVAS receives funding from Vifor Fresenius Medical Care Renal Pharma Ltd., Hoffman La Roche, InflaRx, and the charity Vasculitis UK . NC is supported by The Danish Heart Foundation . KENK was funded privately by Helen and Ejnar Bjørnows Foundation and Knud Højgaards Foundation .

Publisher Copyright:
© 2022

Other keywords

clinical trials
genetics
histology
registries
vasculitis

Access to Document

10.1016/j.ekir.2022.05.018

1-s2.0-S2468024922014164-mainFinal published version, 514 KBLicence: CC BY-NC-ND

Cite this

Egan, A. C., Kronbichler, A., Neumann, I., Bettiol, A., Carlson, N., Cid, M. C., Emmi, G., Gopaluni, S., Harper, L., Hauser, T., Little, M. A., Luqmani, R. A., Mahr, A., McClure, M., Mohammad, A. J., Nelveg-Kristensen, K. E., Ohlsson, S., Peh, C. A., Rutherford, M., ... Jayne, D. R. W. (2022). The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney International Reports, 7(8), 1745-1757. https://doi.org/10.1016/j.ekir.2022.05.018

@article{74037a8fa8f644459e7d42a2d27d9ca7,

title = "The Sound of Interconnectivity; The European Vasculitis Society 2022 Report",

abstract = "The first European Vasculitis Society (EUVAS) meeting report was published in 2017. Herein, we report on developments in the past 5 years which were greatly influenced by the pandemic. The adaptability to engage virtually, at this critical time in society, embodies the importance of networks and underscores the role of global collaborations. We outline state-of-the-art webinar topics, updates on developments in the last 5 years, and proposals for agendas going forward. A host of newly reported clinical trials is shaping practice on steroid minimization, maintenance strategies, and the role of newer therapies. To guide longer-term strategies, a longitudinal 10-year study investigating relapse, comorbidity, malignancy, and survival rates is at an advanced stage. Disease assessment studies are refining classification criteria to differentiate forms of vasculitis more fully. A large international validation study on the histologic classification of anti-neutrophil cytoplasmic antibody (ANCA) glomerulonephritis, recruiting new multicenter sites and comparing results with the Kidney Risk Score, has been conducted. Eosinophilic granulomatosis with polyangiitis (EGPA) genomics offers potential pathogenic subset and therapeutic insights. Among biomarkers, ANCA testing is favoring immunoassay as the preferred method for diagnostic evaluation. Consolidated development of European registries is progressing with an integrated framework to analyze large clinical data sets on an unprecedented scale.",

keywords = "clinical trials, genetics, histology, registries, vasculitis",

author = "Egan, {Allyson C.} and Andreas Kronbichler and Irmgard Neumann and Alessandra Bettiol and Nicholas Carlson and Cid, {Maria C.} and Giacomo Emmi and Seerapani Gopaluni and Lorraine Harper and Thomas Hauser and Little, {Mark A.} and Luqmani, {Raashid A.} and Alfred Mahr and Mark McClure and Mohammad, {Aladdin J.} and Nelveg-Kristensen, {Karl Emil} and Sophie Ohlsson and Peh, {Chen Au} and Matthew Rutherford and Alamo, {Beatriz Sanchez} and Jennifer Scott and M{\aa}rten Segelmark and Smith, {Rona M.} and Szpirt, {Wladimir M.} and Gunnar T{\'o}masson and Giorgio Trivioli and Augusto Vaglio and Michael Walsh and {Wester Trejo}, Maria and Kerstin Westman and Bajema, {Ingeborg M.} and Jayne, {David R.W.}",

note = "Funding Information: The authors acknowledge Dr. Elena Gelain (Nephrology Unit, Meyer Children's Hospital and Department of Biomedical Experimental and Clinical Sciences “Mario Serio,” University of Firenze, Firenze, Italy) for coordinating several EGPA and IgAV activities. EUVAS receives funding from Vifor Fresenius Medical Care Renal Pharma Ltd. Hoffman La Roche, InflaRx, and the charity Vasculitis UK. NC is supported by The Danish Heart Foundation. KENK was funded privately by Helen and Ejnar Bj{\o}rnows Foundation and Knud H{\o}jgaards Foundation. Funding Information: The authors acknowledge Dr. Elena Gelain (Nephrology Unit, Meyer Children{\textquoteright}s Hospital and Department of Biomedical Experimental and Clinical Sciences “Mario Serio,” University of Firenze, Firenze, Italy) for coordinating several EGPA and IgAV activities. EUVAS receives funding from Vifor Fresenius Medical Care Renal Pharma Ltd., Hoffman La Roche, InflaRx, and the charity Vasculitis UK . NC is supported by The Danish Heart Foundation . KENK was funded privately by Helen and Ejnar Bj{\o}rnows Foundation and Knud H{\o}jgaards Foundation . Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = aug,

doi = "10.1016/j.ekir.2022.05.018",

language = "English",

volume = "7",

pages = "1745--1757",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "8",

}

Egan, AC, Kronbichler, A, Neumann, I, Bettiol, A, Carlson, N, Cid, MC, Emmi, G, Gopaluni, S, Harper, L, Hauser, T, Little, MA, Luqmani, RA, Mahr, A, McClure, M, Mohammad, AJ, Nelveg-Kristensen, KE, Ohlsson, S, Peh, CA, Rutherford, M, Alamo, BS, Scott, J, Segelmark, M, Smith, RM, Szpirt, WM, Tómasson, G, Trivioli, G, Vaglio, A, Walsh, M, Wester Trejo, M, Westman, K, Bajema, IM & Jayne, DRW 2022, 'The Sound of Interconnectivity; The European Vasculitis Society 2022 Report', Kidney International Reports, vol. 7, no. 8, pp. 1745-1757. https://doi.org/10.1016/j.ekir.2022.05.018

TY - JOUR

T1 - The Sound of Interconnectivity; The European Vasculitis Society 2022 Report

AU - Egan, Allyson C.

AU - Kronbichler, Andreas

AU - Neumann, Irmgard

AU - Bettiol, Alessandra

AU - Carlson, Nicholas

AU - Cid, Maria C.

AU - Emmi, Giacomo

AU - Gopaluni, Seerapani

AU - Harper, Lorraine

AU - Hauser, Thomas

AU - Little, Mark A.

AU - Luqmani, Raashid A.

AU - Mahr, Alfred

AU - McClure, Mark

AU - Mohammad, Aladdin J.

AU - Nelveg-Kristensen, Karl Emil

AU - Ohlsson, Sophie

AU - Peh, Chen Au

AU - Rutherford, Matthew

AU - Alamo, Beatriz Sanchez

AU - Scott, Jennifer

AU - Segelmark, Mårten

AU - Smith, Rona M.

AU - Szpirt, Wladimir M.

AU - Tómasson, Gunnar

AU - Trivioli, Giorgio

AU - Vaglio, Augusto

AU - Walsh, Michael

AU - Wester Trejo, Maria

AU - Westman, Kerstin

AU - Bajema, Ingeborg M.

AU - Jayne, David R.W.

N1 - Funding Information: The authors acknowledge Dr. Elena Gelain (Nephrology Unit, Meyer Children's Hospital and Department of Biomedical Experimental and Clinical Sciences “Mario Serio,” University of Firenze, Firenze, Italy) for coordinating several EGPA and IgAV activities. EUVAS receives funding from Vifor Fresenius Medical Care Renal Pharma Ltd. Hoffman La Roche, InflaRx, and the charity Vasculitis UK. NC is supported by The Danish Heart Foundation. KENK was funded privately by Helen and Ejnar Bjørnows Foundation and Knud Højgaards Foundation. Funding Information: The authors acknowledge Dr. Elena Gelain (Nephrology Unit, Meyer Children’s Hospital and Department of Biomedical Experimental and Clinical Sciences “Mario Serio,” University of Firenze, Firenze, Italy) for coordinating several EGPA and IgAV activities. EUVAS receives funding from Vifor Fresenius Medical Care Renal Pharma Ltd., Hoffman La Roche, InflaRx, and the charity Vasculitis UK . NC is supported by The Danish Heart Foundation . KENK was funded privately by Helen and Ejnar Bjørnows Foundation and Knud Højgaards Foundation . Publisher Copyright: © 2022

PY - 2022/8

Y1 - 2022/8

N2 - The first European Vasculitis Society (EUVAS) meeting report was published in 2017. Herein, we report on developments in the past 5 years which were greatly influenced by the pandemic. The adaptability to engage virtually, at this critical time in society, embodies the importance of networks and underscores the role of global collaborations. We outline state-of-the-art webinar topics, updates on developments in the last 5 years, and proposals for agendas going forward. A host of newly reported clinical trials is shaping practice on steroid minimization, maintenance strategies, and the role of newer therapies. To guide longer-term strategies, a longitudinal 10-year study investigating relapse, comorbidity, malignancy, and survival rates is at an advanced stage. Disease assessment studies are refining classification criteria to differentiate forms of vasculitis more fully. A large international validation study on the histologic classification of anti-neutrophil cytoplasmic antibody (ANCA) glomerulonephritis, recruiting new multicenter sites and comparing results with the Kidney Risk Score, has been conducted. Eosinophilic granulomatosis with polyangiitis (EGPA) genomics offers potential pathogenic subset and therapeutic insights. Among biomarkers, ANCA testing is favoring immunoassay as the preferred method for diagnostic evaluation. Consolidated development of European registries is progressing with an integrated framework to analyze large clinical data sets on an unprecedented scale.

AB - The first European Vasculitis Society (EUVAS) meeting report was published in 2017. Herein, we report on developments in the past 5 years which were greatly influenced by the pandemic. The adaptability to engage virtually, at this critical time in society, embodies the importance of networks and underscores the role of global collaborations. We outline state-of-the-art webinar topics, updates on developments in the last 5 years, and proposals for agendas going forward. A host of newly reported clinical trials is shaping practice on steroid minimization, maintenance strategies, and the role of newer therapies. To guide longer-term strategies, a longitudinal 10-year study investigating relapse, comorbidity, malignancy, and survival rates is at an advanced stage. Disease assessment studies are refining classification criteria to differentiate forms of vasculitis more fully. A large international validation study on the histologic classification of anti-neutrophil cytoplasmic antibody (ANCA) glomerulonephritis, recruiting new multicenter sites and comparing results with the Kidney Risk Score, has been conducted. Eosinophilic granulomatosis with polyangiitis (EGPA) genomics offers potential pathogenic subset and therapeutic insights. Among biomarkers, ANCA testing is favoring immunoassay as the preferred method for diagnostic evaluation. Consolidated development of European registries is progressing with an integrated framework to analyze large clinical data sets on an unprecedented scale.

KW - clinical trials

KW - genetics

KW - histology

KW - registries

KW - vasculitis

UR - http://www.scopus.com/inward/record.url?scp=85133308445&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2022.05.018

DO - 10.1016/j.ekir.2022.05.018

M3 - Article

AN - SCOPUS:85133308445

SN - 2468-0249

VL - 7

SP - 1745

EP - 1757

JO - Kidney International Reports

JF - Kidney International Reports

IS - 8

ER -

The Sound of Interconnectivity; The European Vasculitis Society 2022 Report

Abstract

Bibliographical note

Other keywords

Access to Document

Fingerprint

Cite this